Trial Profile
A Prospective, Open-label, Multicentre Phase-II Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Physically Fit or Unfit Patients With Previously Untreated Chronic Lymphocytic Leukemia (Cll) With tp53 Deletion (17p-) and/or Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Jun 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary) ; Obinutuzumab (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms CLL2-GiVe
- 26 Jun 2023 Final results assessing the efficacy and safety of obinutuzumab, ibrutinib, and venetoclax in untreated high-risk patients with chronic lymphocytic leukemia, published in the Blood.
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 19 Mar 2022 Status changed from active, no longer recruiting to completed.